Drug intelligence / Profile preview

LY3108743

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY3108743 is an investigational oral drug developed by Eli Lilly for the treatment of type 2 diabetes. It is being studied in the field of endocrinology and metabolic diseases, with clinical trials evaluating its safety and tolerability in both healthy participants and those with type 2 diabetes. The specific mechanism of action has not been publicly disclosed, but it is classified as a small molecule agent[1][3][4].

Beyond the preview

Go deeper on LY3108743.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3108743.

Explore the full profile